Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2–ERG fusion status

Abstract

TMPRSS2–ERG fusion is the most common oncogenic rearrangement in prostate cancer (CaP). Owing to this chromosomal rearrangement one TMPRSS2 allele loses its promoter, and one of the ETS-related gene (ERG) alleles gains that promoter leading to its overexpression in these tumor cells. Some studies suggest that TMPRSS2, an androgen-regulated type II transmembrane serine protease, may have an effect on CaP progression. We hypothesized that a difference in TMPRSS2 expression may be present in vivo between CaP cells with and without TMPRSS2–ERG fusion, or a compensatory mechanism for the allelic loss of TMPRSS2 may balance that expression difference. Therefore, TMPRSS2 mRNA expression was evaluated in microdissected CaP cells with and without TMPRSS2–ERG fusion in 132 CaP patients and analyzed for its correlation with other androgen receptor (AR)-regulated genes and clinicopathological features. In vivo TMPRSS2 expression correlated with that of other AR-regulated genes, including PSA/KLK3 and PMEPA1, offering potential as AR surrogates. A significantly reduced expression of TMPRSS2 was evident in malignant cells harboring TMPRSS2–ERG fusion, but not in CaP cells without TMPRSS2–ERG fusion, further defining these two genetically distinct types of CaP.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Makarov DV, Loeb S, Getzenberg RH, Partin AW . Biomarkers for prostate cancer. Annu Rev Med 2008; 60: 139–151.

    Article  Google Scholar 

  2. Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE . Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 1997; 44: 309–320.

    Article  CAS  Google Scholar 

  3. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59: 4180–4184.

    CAS  PubMed  Google Scholar 

  4. Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O, Vihko P . The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer 2001; 94: 705–710.

    Article  CAS  Google Scholar 

  5. Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E, Saffran DC et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res 2001; 61: 1686–1692.

    CAS  PubMed  Google Scholar 

  6. Vaarala MH, Porvari KS, Kellokumpu S, Kyllönen AP, Vihko PT . Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol 2001; 193: 134–140.

    Article  CAS  Google Scholar 

  7. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847–3852.

    Article  CAS  Google Scholar 

  8. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–648.

    Article  CAS  Google Scholar 

  9. Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005; 388: 967–972.

    Article  CAS  Google Scholar 

  10. Veitia RA, Bottani S, Birchler JA . Cellular reactions to gene dosage imbalance: genomic, transcriptomic and proteomic effects. Trends Genet 2008; 24: 390–397.

    Article  CAS  Google Scholar 

  11. Aït Yahya-Graison E, Aubert J, Dauphinot L, Rivals I, Prieur M, Golfier G et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet 2007; 81: 475–491.

    Article  Google Scholar 

  12. Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 2008; 215: 118–125.

    Article  CAS  Google Scholar 

  13. Bi X, He H, Ye Y, Dai Q, Han Z, Liang Y et al. Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer. Med Oncol 2009 26 February [e-pub ahead of print].

  14. Kim TS, Heinlein C, Hackman RC, Nelson PS . Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 2006; 26: 965–975.

    Article  CAS  Google Scholar 

  15. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L et al. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008; 14: 758–763.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grant 5R01 DK065977 for SS and GP from the National Institutes of Health. The views expressed in this paper are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or the US Government.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to S Srivastava or G Petrovics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mwamukonda, K., Chen, Y., Ravindranath, L. et al. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2–ERG fusion status. Prostate Cancer Prostatic Dis 13, 47–51 (2010). https://doi.org/10.1038/pcan.2009.28

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.28

Keywords

This article is cited by

Search

Quick links